Acumen Pharmaceuticals
(NASDAQ) ABOS
Acumen Pharmaceuticals Financials at a Glance
Market Cap
$169.01M
Revenue (TTM)
$0.00
Net Income (TTM)
-$113.28M
EPS (TTM)
-$1.86
P/E Ratio
-1.26
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$2.32
Volume
26,599
Open
$2.38
Price
$2.32
Volume
26,599
Open
$2.38
Previous Close
$2.32
Daily Range
$2.31 - $2.41
52-Week Range
$1.10 - $3.60
Estimated Earnings Date
Aug 11, 2026
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$2.32
Volume
26,599
Open
$2.38
Previous Close
$2.32
Daily Range
$2.31 - $2.41
52-Week Range
$1.10 - $3.60
Estimated Earnings Date
Aug 11, 2026
ABOS News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Acumen Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
61
CEO
Daniel J. O'Connell, MBA
Website
www.acumenpharm.comHeadquarters
Newton, VA 22902, US
ABOS Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-93%
Return on Capital
-1%
Return on Assets
-85%
Earnings Yield
-79.37%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$169.01M
Shares Outstanding
72.23M
Volume
26.60K
Avg. Volume
535.09K
Financials (TTM)
Gross Profit
$0.00
Operating Income
-$123.83M
EBITDA
-$116.93M
Operating Cash Flow
-$115.54M
Capital Expenditure
-$88.00K
Free Cash Flow
-$115.63M
Cash & ST Invst.
$116.87M
Total Debt
$31.31M
Acumen Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
-$46.00K
N/A
Gross Margin
0.00%
N/A
Market Cap
$169.01M
N/A
Market Cap/Employee
$2.77M
N/A
Employees
61
N/A
Net Income
-$20.74M
+28.0%
EBITDA
-$19.62M
+29.2%
Quarterly Fundamentals
Total Cash
$128.40M
-13.9%
Total Debt
$31.16M
+7.5%
Accounts Receivable
$772.00K
+105.3%
Inventory
$0.00
N/A
Long Term Debt
$16.92M
-41.4%
Short Term Debt
$14.35M
+10299.3%
Return on Assets
-84.77%
N/A
Return on Invested Capital
-1.10%
N/A
Free Cash Flow
-$24.13M
+29.5%
Operating Cash Flow
-$24.13M
+29.3%